N
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
Price:
29.76
USD
-2.3%
Market Cap:
$3.4B
Relative Value
There is not enough data to reliably calculate the relative value of NAMS.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NAMS
Relative Value
Base Case
Not Available
Multiples Across Competitors
NAMS Competitors Multiples
NewAmsterdam Pharma Company NV Competitors
NewAmsterdam Pharma Company NV Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NL |
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
3.5B USD | 26.6 | -18 | -17.1 | -17.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.8B USD | 5.9 | 86.7 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.3B USD | 5.1 | 24.2 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172B USD | 5.8 | 20.1 | 12.6 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.2B USD | 9.6 | 29.3 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.6B USD | 5.4 | 17.2 | 12.7 | 14.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.7B AUD | 3.1 | 33.9 | 11.2 | 14.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
42.6B USD | 11.3 | 133.5 | 74.7 | 83 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
